The Carlyle Group . 4.625% Subordinated Notes Due 2061 Earnings Calls
| Release date | May 08, 2026 |
| EPS estimate | - |
| EPS actual | -$0.370 |
| Revenue estimate | - |
| Revenue actual | 254M |
| Release date | Feb 27, 2026 |
| EPS estimate | - |
| EPS actual | $0.690 |
| Revenue estimate | - |
| Revenue actual | 1.901B |
| Release date | Sep 29, 2023 |
| EPS estimate | - |
| EPS actual | $0.224 |
| Revenue estimate | - |
| Revenue actual | 716.6M |
| Release date | Jun 29, 2023 |
| EPS estimate | - |
| EPS actual | -$0.272 |
| Revenue estimate | - |
| Revenue actual | 462.1M |
Last 4 Quarters for The Carlyle Group . 4.625% Subordinated Notes Due 2061
Below you can see how CGABL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jun 29, 2023 |
| Price on release | $18.27 |
| EPS estimate | - |
| EPS actual | -$0.272 |
| Date | Price |
|---|---|
| Jun 23, 2023 | $17.96 |
| Jun 26, 2023 | $18.21 |
| Jun 27, 2023 | $18.16 |
| Jun 28, 2023 | $18.25 |
| Jun 29, 2023 | $18.27 |
| Jun 30, 2023 | $18.13 |
| Jul 03, 2023 | $18.41 |
| Jul 05, 2023 | $18.54 |
| Jul 06, 2023 | $17.93 |
| 4 days before | 1.73% |
| 4 days after | -1.86% |
| On release day | -0.766% |
| Change in period | -0.167% |
| Release date | Sep 29, 2023 |
| Price on release | $16.42 |
| EPS estimate | - |
| EPS actual | $0.224 |
| Date | Price |
|---|---|
| Sep 25, 2023 | $16.09 |
| Sep 26, 2023 | $16.27 |
| Sep 27, 2023 | $16.26 |
| Sep 28, 2023 | $16.15 |
| Sep 29, 2023 | $16.42 |
| Oct 02, 2023 | $16.33 |
| Oct 03, 2023 | $16.33 |
| Oct 04, 2023 | $16.48 |
| Oct 05, 2023 | $16.50 |
| 4 days before | 2.05% |
| 4 days after | 0.487% |
| On release day | -0.548% |
| Change in period | 2.55% |
| Release date | Feb 27, 2026 |
| Price on release | $17.59 |
| EPS estimate | - |
| EPS actual | $0.690 |
| Date | Price |
|---|---|
| Feb 23, 2026 | $17.59 |
| Feb 24, 2026 | $17.44 |
| Feb 25, 2026 | $17.59 |
| Feb 26, 2026 | $17.56 |
| Feb 27, 2026 | $17.59 |
| Mar 02, 2026 | $17.58 |
| Mar 03, 2026 | $17.49 |
| Mar 04, 2026 | $17.55 |
| Mar 05, 2026 | $17.55 |
| 4 days before | 0% |
| 4 days after | -0.227% |
| On release day | -0.0569% |
| Change in period | -0.227% |
| Release date | May 08, 2026 |
| Price on release | $17.15 |
| EPS estimate | - |
| EPS actual | -$0.370 |
| Date | Price |
|---|---|
| May 04, 2026 | $17.08 |
| May 05, 2026 | $16.93 |
| May 06, 2026 | $16.86 |
| May 07, 2026 | $16.85 |
| May 08, 2026 | $17.15 |
| May 11, 2026 | $17.11 |
| May 12, 2026 | $17.00 |
| May 13, 2026 | $16.88 |
| May 14, 2026 | $16.93 |
| 4 days before | 0.410% |
| 4 days after | -1.28% |
| On release day | -0.233% |
| Change in period | -0.88% |
The Carlyle Group . 4.625% Subordinated Notes Due 2061 Earnings Call Transcript Summary of Q1 2026
Carlyle reported a strong Q1 2026 driven by record U.S. buyout realizations (> $12B), robust inflows ($13B total with $6.8B to AlpInvest and $3.9B to Global Credit), $300M fee-related earnings at a 47% margin, and $327M distributable earnings ($0.89/sh). Key operational highlights: record AlpInvest AUM ($107B) and inflows, Global Credit AUM $209B with strengthened credit metrics (direct lending nonaccrual 1%, structured credit default ~50 bps), $10B deployments in the quarter, and notable announced transactions including an $8B BASF coatings carve-out and a $3B MAI Capital acquisition. Carlyle closed an innovative, capital-efficient solution anchored by a $5B-plus cornerstone commitment tied to the next vintage U.S. buyout fund, demonstrating product innovation and LP demand. Realizations accelerated capital returns (record returns to U.S. buyout investors, CP VII DPI >70%), but near-term realized carry was modest due to the composition of exits (many from funds not yet in carry). Balance sheet remains healthy (~$5B of balance sheet assets attributable to shareholders, ~$14/sh), dividend maintained at $0.35/share, and $205M in share repurchases in the quarter with $1.9B remaining authorization. Management reaffirmed confidence in previously stated medium-term targets (by end-2028: ~$200B inflows, $1.9B FRE, $6+ DE/sh) and expects FRE growth to accelerate as fundraising and signed transactions drive higher management and transaction fees in coming quarters.
Sign In
Buy CGABL